{
  "version": 1,
  "event_id": "evt_7b0a0a9232e84f9e",
  "url": "https://xiyu.news/events/evt_7b0a0a9232e84f9e/",
  "json": "https://xiyu.news/api/events/evt_7b0a0a9232e84f9e.json",
  "type": "other",
  "status": "monitoring",
  "category": "technology",
  "title": {
    "zh": "FDA批准首款转移性胰腺癌靶向疗法",
    "en": "FDA Approves First Targeted Therapy for Metastatic Pancreatic Cancer"
  },
  "current_state": {
    "zh": "FDA批准首款转移性胰腺癌靶向疗法",
    "en": "FDA Approves First Targeted Therapy for Metastatic Pancreatic Cancer"
  },
  "first_seen_at": "2026-08-27T08:00:00+08:00",
  "last_updated_at": "2026-08-27T08:00:00+08:00",
  "last_material_change_at": "2026-08-27T08:00:00+08:00",
  "confidence": 0.75,
  "updates_count": 1,
  "sources_count": 1,
  "entities": [
    "approves",
    "cancer",
    "fda",
    "first",
    "metastatic",
    "pancreatic",
    "pancreatic-cancer",
    "targeted",
    "targeted-therapy",
    "therapy"
  ],
  "identifiers": [],
  "topics": [
    "fda",
    "medical-breakthrough",
    "pancreatic-cancer",
    "ras-inhibitor",
    "targeted-therapy"
  ],
  "updates": [
    {
      "update_id": "upd_1e3427813fc27a6c",
      "event_id": "evt_7b0a0a9232e84f9e",
      "occurred_at": "2026-08-27T08:00:00+08:00",
      "published_at": "2026-08-27T08:00:00+08:00",
      "first_seen_at": "2026-08-27T08:00:00+08:00",
      "time_precision": "edition",
      "update_type": "initial",
      "material_change": true,
      "title_zh": "FDA批准首款转移性胰腺癌靶向疗法",
      "title_en": "FDA Approves First Targeted Therapy for Metastatic Pancreatic Cancer",
      "what_changed_zh": "FDA批准首款转移性胰腺癌靶向疗法",
      "what_changed_en": "FDA Approves First Targeted Therapy for Metastatic Pancreatic Cancer",
      "current_state_zh": "FDA批准首款转移性胰腺癌靶向疗法",
      "current_state_en": "FDA Approves First Targeted Therapy for Metastatic Pancreatic Cancer",
      "detailed_summary_zh": "美国FDA批准了首款针对转移性胰腺癌的靶向疗法，这是一种口服小分子RAS抑制剂。这是RAS靶向药物首次获批用于该适应症，攻克了曾被视为“不可成药”的靶点。\n\n胰腺癌是最致命的恶性肿瘤之一，绝大多数病例存在RAS突变。此次批准验证了靶向KRAS这一长期追求的方向，可能为多种RAS突变癌症的类似疗法铺平道路。\n\n此次批准从FDA受理新药申请（NDA）到获批仅用了约一个月，这是在FDA的CNPV试点计划下实现的，远快于传统的优先审评（约8个月）和标准审评（约12个月）周期。超过90%的胰腺导管腺癌存在RAS突变，该药物属于RAS(ON)多选择性抑制剂类别。",
      "detailed_summary_en": "The FDA approved the first-in-class targeted therapy for metastatic pancreatic cancer, an oral small-molecule RAS inhibitor. This is the first time a RAS-targeted drug has been cleared for this indication, overcoming a protein previously deemed undruggable.\n\nPancreatic cancer is one of the most lethal malignancies, and the vast majority of cases harbor RAS mutations. This approval validates a long-sought approach to target KRAS and could pave the way for similar therapies across many other RAS-mutant cancers.\n\nThe approval was granted roughly one month after the FDA accepted the new drug application under the agency's CNPV pilot program, much faster than typical priority (8 months) or standard (12 months) review timelines. RAS mutations occur in over 90% of pancreatic ductal adenocarcinomas, and the drug belongs to the RAS(ON) multiselective inhibitor class.",
      "background_zh": "",
      "background_en": "",
      "community_discussion_zh": "",
      "community_discussion_en": "",
      "market_impact_zh": "",
      "market_impact_en": "",
      "importance_score": 9.0,
      "references": [],
      "confidence": 0.75,
      "story_ids": [
        "hackernews:story:49451675"
      ],
      "sources": [
        {
          "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer",
          "label": "leopoldj",
          "source_type": "hackernews",
          "official": false
        }
      ]
    }
  ]
}